Results 221 to 230 of about 721,847 (303)

Correction to: Left atrial shunting devices: why, what, how, and… when? [PDF]

Heart Fail Rev
De Lorenzo LA, Baratto C, Sala D, Perego GB, Caravita S.   +4 more
europepmc   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

Design and rationale of the RISC-trial: multicentre <i>R</i>CT to assess <i>i</i>mmediate discharge of <i>s</i>yncope patients admitted to the (<i>c</i>ardiac) emergency room. [PDF]

Eur Heart J Open
Boel TT, Peeters SYG, van Alem AP, Boogers MJ, Bootsma M, van den Dorpel MA, Firouzi M, Groothuis JGJ, Hemels MEW, Houtgraaf JH, Jansen WPJ, de Jong JSY, Jongenotter M, Kaal ECA, Koomen EM, Langerak SE, Mairuhu G, Mullaart NE, van Rees JB, Samim M, Wierda E, van Zanten S, van Zoelen A, van Barreveld M, Croon PM, Dijkgraaf MGW, Tijssen JGP, De Groot JR, de Lange FJ.   +28 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Bradyarrhythmias and Brugada syndrome: clinical features, long-term outcome and prognostic implications-the BruBra study. [PDF]

Europace
Özkartal T, Bergonti M, Caputo ML, Pannone L, de Asmundis C, Compagnucci P, Casella M, Berne P, Casu G, Migliore F, Martini N, Faccenda D, Scheirlynck E, Conte G.   +13 more
europepmc   +1 more source

N‐terminal pro‐brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi, Masaomi Nangaku, Tadashi Sofue, Tatsuo Kagimura, Ichiei Narita   +4 more
wiley   +1 more source

Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac-kidney-metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project. [PDF]

Eur Heart J Open
Tian X, Liu X, Zhao J, Han X, Gu T, Chen KY, Korantzopoulos P, Lip GYH, Liu T.   +8 more
europepmc   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

Clinical value of anti-desmoglein-2 antibodies in arrhythmogenic right ventricular cardiomyopathy: real-world evidence. [PDF]

Europace
Joseph S, Borowiec K, Woźniak O, Chatterjee D, Fatah M, Silbiger V, Kowalik I, Skrzypczyńska-Banasik U, Kowalik E, Kowalski M, Biernacka EK, Hamilton RM.   +11 more
europepmc   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source